<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467593</url>
  </required_header>
  <id_info>
    <org_study_id>MATTERS 1</org_study_id>
    <nct_id>NCT04467593</nct_id>
  </id_info>
  <brief_title>Safety Study of Whole Body Hyperthermia for Advanced Cancer</brief_title>
  <acronym>MATTERS</acronym>
  <official_title>A Mono-centric, First In-human (FIH), Safety and Preliminary Efficacy Study of (Neo)Adjuvant, Model-based, Whole-body Hyperthermia (WBHT) Treatment in Advanced Solid Cancer Patients or Stage IV (TxNxM1) Metastatic Pancreatic Adenocarcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElmediX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElmediX</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Millions of patients die of cancer every year. There are several methods to treat cancer,&#xD;
      including surgery, chemotherapy, radiotherapy and immunotherapy. Recently, hyperthermia&#xD;
      therapy started playing a role in cancer therapy. It has shown effect in animal experiments&#xD;
      and clinical practice. The sponsor has developed a novel device to use hyperthermia for&#xD;
      advanced cancer. This study is to prove the safety in human patients of this device &amp; therapy&#xD;
      and get the first data on efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse device events (ADEs) in relation to the medical device</measure>
    <time_frame>4 weeks after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of related clinically significant abnormalities on electrocardiogram (ECG), vital signs, physical examination and laboratory parameters</measure>
    <time_frame>4 weeks after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) related to WBHT treatment alone or in combination with FOLFIRINOX, FOLFOX, gemcitabine/ nab-paclitaxel or gemcitabine alone</measure>
    <time_frame>4 weeks after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evolution of CA19-9 (U/ml)</measure>
    <time_frame>4 weeks after last treatment</time_frame>
    <description>The evolution of this clinically significant biological parameter will be measured compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of CEA (ng/ml)</measure>
    <time_frame>4 weeks after last treatment</time_frame>
    <description>The evolution of this clinically significant biological parameter will be measured compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>based on the three primary outcome measures, guidance will be drafted for phase II treatment duration in combination with chemotherapy dosing.</measure>
    <time_frame>4 weeks after last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Pancreatic Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest whole-body hyperthermia duration with acceptable side effects from cohort A1 will be applied to three additional patients with advanced solid cancer, once a week and for 15 days in total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three pancreatic cancer patients will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15) using the device and in combination with the standard of care chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nab-paclitaxel or gemcitabine alone).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest whole-body hyperthermia duration with acceptable side effects from cohort B1 will be applied in combination with chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nabpaclitaxel or gemcitabine alone) to three additional pancreatic cancer patients, once a week and for 15 days in total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Whole body hyperthermia device</intervention_name>
    <description>Whole body hyperthermia to treat stage IV cancer patients</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Whole body hyperthermia device with FOLFIRINOX or FOLFOX or gemcitabine/nab-paclitaxel or gemcitabine</intervention_name>
    <description>Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients between 18- and 75-years of age at time of signing the informed consent&#xD;
&#xD;
          2. Patients with advanced solid cancer (for cohort A only) or metastatic pancreatic&#xD;
             adenocarcinoma confirmed by histology (for cohort B only)&#xD;
&#xD;
          3. Patients previously treated (for cohort A and B) or under treatment with standard of&#xD;
             care treatment (cohort B only)&#xD;
&#xD;
          4. WHO performance status ≤ 1(see appendix V)&#xD;
&#xD;
          5. BMI ≤ 32 kg/m2&#xD;
&#xD;
          6. Weight ≤ 100 kg&#xD;
&#xD;
          7. Height ≤ 1,90 m&#xD;
&#xD;
          8. Adequate liver structure (confirmed by CT scan) allowing the placement of the liver&#xD;
             sensor&#xD;
&#xD;
          9. No (prostate) pathology that would interfere with the placement of the bladder&#xD;
             catheter&#xD;
&#xD;
         10. Adequate bone marrow function defined as&#xD;
&#xD;
               1. white blood cell count ≥ 2000/µl&#xD;
&#xD;
               2. neutrophils ≥ 1500 cells/μL&#xD;
&#xD;
               3. platelets ≥ 100 x 109/L&#xD;
&#xD;
               4. hemoglobin ≥ 10 g/dl documented within 1 week prior to first treatment&#xD;
&#xD;
         11. Adequate coagulation defined as&#xD;
&#xD;
               1. Quick-value ≥ 70% (± 1.15 x ULN)&#xD;
&#xD;
               2. aPTT ≤ 2.5 x ULN, documented within 1 week prior to first treatment&#xD;
&#xD;
               3. Fibrinogen ± 1.15 x ULN&#xD;
&#xD;
               4. D-dimers ± 1.15 x ULN&#xD;
&#xD;
               5. Protein-C ± 1.15 x ULN&#xD;
&#xD;
               6. Factor VIII ± 1.15 x ULN&#xD;
&#xD;
               7. Factor IX ± 1.15 x ULN&#xD;
&#xD;
               8. Von Willebrand Factor ± 1.15 x ULN&#xD;
&#xD;
         12. Adequate liver function defined as&#xD;
&#xD;
               1. Transaminases (AST, ALT) ≤ 2.5 x ULN or ≤ 5.0 in presence of liver metastasis&#xD;
&#xD;
               2. bilirubin ≤ 2 x ULN documented&#xD;
&#xD;
         13. Adequate renal function defined as&#xD;
&#xD;
               1. serum creatinine ≤ 1.6 mg/dL (male); ≤ 1.3 mg/dL (female);&#xD;
&#xD;
               2. albumin ≥ 30g/L&#xD;
&#xD;
               3. calculated eGFR ≥ 60 mL/min (CKD-EPI equation) documented within 1 week prior to&#xD;
                  randomization&#xD;
&#xD;
         14. No blood donation 3 months prior to the WBHT treatment&#xD;
&#xD;
         15. No participation in other clinical trial 4 weeks prior to the WBHT treatment&#xD;
&#xD;
         16. No biological therapy 4 weeks prior to the WBHT treatment or during WBHT treatment&#xD;
&#xD;
         17. No surgery 4 weeks prior to the WBHT treatment&#xD;
&#xD;
         18. No radiotherapy 3 weeks prior to the WBHT treatment or during WBHT treatment&#xD;
&#xD;
         19. No chemotherapy 1 week prior to the WBHT treatment (for cohort A and B) or during WBHT&#xD;
             treatment (for Cohort A)&#xD;
&#xD;
         20. No transdermal patches&#xD;
&#xD;
         21. No piercings (internally or externally)&#xD;
&#xD;
         22. Life expectancy of at least 18 weeks&#xD;
&#xD;
         23. Effective contraception for both male and female patients if applicable. Women of&#xD;
             childbearing potential must have negative blood pregnancy test at screening visit.&#xD;
&#xD;
         24. Written informed consent must be given according to good clinical practice and&#xD;
             national/local regulations.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding women (based on HCG levels)&#xD;
&#xD;
          2. Presence of brain metastasis (known or suspected)&#xD;
&#xD;
          3. Other malignant diseases in the medical history during the last 5 years (exceptions:&#xD;
             carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the&#xD;
             skin)&#xD;
&#xD;
          4. Serious medical risk factors involving any of the major organ systems, including high&#xD;
             cardiovascular risk, coronary stenting or myocardial infarction in the last year&#xD;
&#xD;
          5. Clinically significant pulmonary disease which might interfere with mechanical&#xD;
             ventilation&#xD;
&#xD;
          6. History of autonomic dysfunction (due to the influence on skin blood flow)&#xD;
&#xD;
          7. History of malignant hyperthermia or a positive diagnostic test (Caffeine-Halothane&#xD;
             Contracture test) in case of family history of malignant hyperthermia.&#xD;
&#xD;
          8. History of untreated endocrine pathology (e.g. diabetes type II, hyper- or&#xD;
             hypothyroidism).&#xD;
&#xD;
          9. Primary diabetes type I (due to vascular complications)&#xD;
&#xD;
         10. Known allergies to drugs that will be used during the trial (e.g. anesthetic,&#xD;
             analgesic, (chemotherapy used in cohort B))&#xD;
&#xD;
         11. Active infections not controlled by medication&#xD;
&#xD;
         12. Severe, non-healing wounds, ulcers or bone fractures&#xD;
&#xD;
         13. Organ allografts requiring immunosuppressive therapy&#xD;
&#xD;
         14. (History of) clinically significant (investigator decision) psychiatric disorder&#xD;
             and/or psychosocial disorder that may interfere with adequate compliance to the&#xD;
             protocol or signature of the informed consent&#xD;
&#xD;
         15. Other clinically significant disease which could impair the patient's ability to&#xD;
             participate in the study according to the investigator's opinion&#xD;
&#xD;
         16. Participation in another clinical trial during this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Peeters, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oleg Rudenko, MD MSc</last_name>
    <phone>+3215262981</phone>
    <email>oleg.rudenko@elmedix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivana Gorbaslieva, MSc</last_name>
    <phone>+3215262981</phone>
    <email>ivana.gorbaslieva@elmedix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Peeters, Professor</last_name>
      <phone>+3238213000</phone>
      <email>oncologie@uza.be</email>
    </contact>
    <investigator>
      <last_name>Dirk Ysebaert, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vera Saldien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

